BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, Laferl H, Stättermayer AF, Scherzer T, Strassl R, Holzmann H, Steindl-munda P, Ferenci P. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013;38:118-23. [DOI: 10.1111/apt.12350] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Ferenci P. Viral hepatitis: cure of chronic hepatitis C--required length of follow-up? Nat Rev Gastroenterol Hepatol 2015;12:10-1. [PMID: 25421584 DOI: 10.1038/nrgastro.2014.198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Fernández-montero JV, Vispo E, Barreiro P, Mendoza C, Labarga P, Soriano V. Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. Curr Hepatitis Rep 2013;12:269-75. [DOI: 10.1007/s11901-013-0179-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Vaidya A, Perry CM. Simeprevir: first global approval. Drugs. 2013;73:2093-2106. [PMID: 24293133 DOI: 10.1007/s40265-013-0153-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
4 Hajiaghamohammadi A, Samimi R, Miroliaee A, Kazemifar AM, Nazem M. Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients. Glob J Health Sci 2014;7:75-81. [PMID: 25948447 DOI: 10.5539/gjhs.v7n3p75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 An J, Kim KW, Han S, Lee J, Lim YS. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39:1418-1426. [PMID: 24754260 DOI: 10.1111/apt.12771] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
6 Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015;8:298-312. [PMID: 26327920 DOI: 10.1177/1756283X15587481] [Cited by in Crossref: 73] [Cited by in F6Publishing: 23] [Article Influence: 10.4] [Reference Citation Analysis]
7 Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. Intern Med 2018;57:951-6. [PMID: 29225269 DOI: 10.2169/internalmedicine.9671-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Flisiak R, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Simon K, Piekarska A, Tronina O, Tuchendler E, Garlicki A. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. J Viral Hepat 2018;25:1298-305. [PMID: 29888828 DOI: 10.1111/jvh.12945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zoulim F, Moreno C, Lee SS, Buggisch P, Horban A, Lawitz E, Corbett C, Lenz O, Fevery B, Verbinnen T, Shukla U, Jessner W. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. Virol J 2018;15:26. [PMID: 29378602 DOI: 10.1186/s12985-018-0936-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Howe AY, Long J, Nickle D, Barnard R, Thompson S, Howe J, Alves K, Wahl J. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Res 2015;113:71-8. [PMID: 25446895 DOI: 10.1016/j.antiviral.2014.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
11 Del Bello A, Abravanel F, Alric L, Lavayssiere L, Lhomme S, Bellière J, Izopet J, Kamar N. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents. Transpl Infect Dis 2019;21:e13093. [PMID: 30972874 DOI: 10.1111/tid.13093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Rutter K, Stättermayer AF, Beinhardt S, Scherzer T, Steindl-munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 2015;41:521-31. [DOI: 10.1111/apt.13085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
13 Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62:683-694. [PMID: 26787172 DOI: 10.1093/cid/civ948] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 29.7] [Reference Citation Analysis]
14 Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, Gonzalez T, Goodman Z, Yang Z. Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr. 2017;64:89-94. [PMID: 27111344 DOI: 10.1097/mpg.0000000000001239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
15 Hanafy AS, Seleem WM, Basha MAA, Marei AM. Residual hepatitis C virus in peripheral blood mononuclear cell as a risk factor for hepatocellular carcinoma after achieving a sustained virological response: a dogma or fiction. Eur J Gastroenterol Hepatol 2019;31:1275-82. [PMID: 31149912 DOI: 10.1097/MEG.0000000000001459] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Agi E, Asghari S, Namvar A, Khairkhah N, Naderi N, Anvar A, Azizi Saraji A, Bolhassani A; Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents. JoMMID 2020;8:1-6. [DOI: 10.29252/jommid.8.1.1] [Reference Citation Analysis]
17 Höner zu Siederdissen C, Manns MP, Cornberg M. [Which treatment options are validated for chronic viral hepatitis?]. Internist (Berl) 2013;54:1427-8, 1430-3. [PMID: 24258199 DOI: 10.1007/s00108-013-3319-3] [Reference Citation Analysis]
18 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
19 Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gómez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect 2016;22:839-45. [PMID: 27677698 DOI: 10.1016/j.cmi.2016.09.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
20 Attar BM, Van Thiel D. A New Twist to a Chronic HCV Infection: Occult Hepatitis C. Gastroenterol Res Pract. 2015;2015:579147. [PMID: 26221136 DOI: 10.1155/2015/579147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
21 Hayashi K, Ishigami M, Yasuda S, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Hirooka Y, Goto H. Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. Hepatol Res 2018;48:E78-86. [PMID: 28643404 DOI: 10.1111/hepr.12929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
22 Ferenci P, Rutter K. Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral--authors' reply. Aliment Pharmacol Ther 2013;38:558. [PMID: 23937467 DOI: 10.1111/apt.12420] [Reference Citation Analysis]
23 Mishra A, Younossi Z. Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013;38:557-8. [PMID: 23937466 DOI: 10.1111/apt.12419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int 2018;38:821-33. [PMID: 28941023 DOI: 10.1111/liv.13596] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]